10-K: ProAssurance Reports Improved Operating Ratios Amidst Merger Progress

ProAssurance Corporation reported improved operating and combined ratios for 2025, driven by significant favorable reserve development, as it progresses towards a cash acquisition by The Doctors Company.

Summary

• Net income for 2025 was $50.9 million, a decrease from $52.7 million in 2024.
• Diluted earnings per share decreased to $0.99 in 2025 from $1.03 in 2024.
• Net premiums written decreased by 3.9% to $916.9 million in 2025 from $953.7 million in 2024, primarily due to strategic profitability actions and ceased participation in Syndicate 1729.
• The combined ratio improved to 106.6% in 2025 from 109.4% in 2024, driven by favorable loss development.
• The operating ratio improved to 89.8% in 2025 from 94.5% in 2024.
• Non-GAAP operating return on equity (ROE) increased to 6.6% in 2025 from 4.4% in 2024.
• Book value per share increased to $26.24 at December 31, 2025, from $23.49 at December 31, 2024.
• The company recognized $90.3 million in net favorable prior accident year reserve development in 2025, significantly higher than $40.2 million in 2024.
• Transaction-related costs associated with the proposed merger totaled $16.4 million in 2025.
• Regulatory approvals for the merger with The Doctors Company are pending in California and Pennsylvania, with an anticipated closing by June 30, 2026.
• The company suspended its quarterly cash dividend in Q2 2023 and used available capital for share repurchases, with $55.9 million remaining authorization as of February 18, 2026.
• The company entered into a Letter of Intent (LOI) for the sale of its Birmingham, AL property in December 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing. While top-line revenue and net income saw slight declines, core insurance profitability metrics like the combined and operating ratios improved, driven by strong favorable reserve development. The progress towards the merger with The Doctors Company provides a clear path for shareholder value realization, despite some pending regulatory uncertainties.

Positives

• The combined ratio improved to 106.6% in 2025 from 109.4% in 2024, indicating better underwriting profitability.
• The operating ratio improved to 89.8% in 2025 from 94.5% in 2024, reflecting enhanced overall profitability.
• Net favorable prior accident year reserve development significantly increased to $90.3 million in 2025 from $40.2 million in 2024, primarily from Medical Professional Liability and Medical Technology Liability lines.
• Net investment income increased by $12.4 million to $156.5 million in 2025, driven by higher average book yields in the current interest rate environment.
• Non-GAAP operating return on equity (ROE) improved to 6.6% in 2025 from 4.4% in 2024.
• Book value per share increased by $2.75 to $26.24 at December 31, 2025, largely due to unrealized holding gains on the fixed income investment portfolio.
• The company's insurance subsidiaries maintain a favorable A (Excellent) claims paying rating from AM Best, and the holding company has an A+ debt rating with a stable outlook.
• Several key regulatory approvals for the merger with The Doctors Company have been received, including from the FTC and insurance regulators in Alabama, DC, Illinois, Missouri, Texas, and Vermont.
• Successful implementation of medical cost management initiatives in the Workers' Compensation segment has led to observed improvements in average medical cost per claim.

Negatives

• Net premiums written decreased by 3.9% to $916.9 million in 2025, and net premiums earned decreased by 3.5% to $934.2 million, reflecting a lower volume of written premium due to strategic actions and ceased participation in Syndicate 1729.
• Net income decreased to $50.9 million in 2025 from $52.7 million in 2024.
• The underwriting expense ratio increased to 35.4% in 2025 from 33.0% in 2024, partly due to $16.4 million in transaction-related costs for the proposed merger.
• The effective tax rate increased significantly to 29.4% in 2025 from 16.4% in 2024, partly due to non-deductible transaction-related costs and executive compensation limitations.
• Foreign currency exchange rate movements resulted in a loss of $10.9 million in 2025, compared to a gain of $6.7 million in 2024, contributing to a decrease in other income.
• The Workers' Compensation Insurance segment experienced higher than expected loss trends in average cost per claim, primarily from increased medical costs, leading to an increase in the full-year current accident year net loss ratio to 77% in Q4 2025.
• Retention losses in the Medical Professional Liability business are noted due to a competitive market and the company's pursuit of rate adequacy.
• Participation in Lloyd's Syndicates 1729 and 6131 is in run-off, with Syndicate 6131's 2021 underwriting year remaining open due to aviation exposures related to Russia's invasion of Ukraine.
• The company sold the renewal rights for its legal professional liability business, indicating an exit from this line.

Risks

• Changes in general economic conditions, including inflation (medical and social) and unemployment, could affect business plans.
• Regulatory, legislative, and judicial actions or decisions, including tort reforms, could impact business operations and profitability.
• Formation or dissolution of state-sponsored insurance entities could alter the private insurance market.
• Changes in interest, tax, and foreign currency exchange rates could affect investment performance and financial results.
• Performance of financial markets could adversely affect investment fair values or liquidity.
• Uncertainties inherent in the estimate of loss and loss adjustment expense reserves and reinsurance recoverables could lead to material adjustments.
• The availability, cost, quality, or collectability of reinsurance could impact risk exposure.
• Litigation outcomes, including mass torts and allegations of bad faith, could result in significant losses.
• Loss or consolidation of independent agents, agencies, brokers, or brokerage firms could adversely affect business acquisition.
• The availability, integrity, and security of technology infrastructure, including susceptibility to cyber-attacks and the impact of AI, pose operational and financial risks.
• Catastrophes, natural or man-made, including pandemics and acts of terrorism, could materially affect business and investment results.
• Changes to ratings assigned by rating agencies could limit new business or impact liquidity.
• Provisions in charter documents, Delaware law, and state insurance laws may impede attempts to replace management or a takeover.
• State insurance restrictions may prohibit assets held by insurance subsidiaries from being used for general corporate purposes.
• Taxing authorities could challenge tax positions, leading to additional costs.
• Numerous risks and uncertainties are associated with the proposed acquisition by The Doctors Company, including failure to satisfy closing conditions (e.g., regulatory approvals in California and Pennsylvania), stock price fluctuation, potential litigation, business disruption, retention of key personnel, diversion of management's attention, adverse business reactions, restrictions during the pendency, unexpected costs, competitor behavior, and termination fees.
• The company is dependent on dividends and other payments from its operating subsidiaries, which are subject to regulatory restrictions.

Future Outlook

The company anticipates closing the merger transaction with The Doctors Company by June 30, 2026, pending remaining regulatory approvals in California and Pennsylvania. Management aims to achieve a long-term ROE of 700 basis points above the 10-year U.S. Treasury rate, emphasizing rate adequacy, selective underwriting, data analytics, effective claims management, operational efficiency, and prudent investment management. The company expects continued pressure on workers' compensation rates due to state loss cost reductions but is implementing medical cost management initiatives to address severity trends. Investments in AI and process automation are ongoing to enhance risk selection, decision-making, and workflows.

Management Comments

• We believe that this transaction will deliver significant value to our shareholders.
• We believe we have stayed ahead of many in the space in achieving rate levels in MPL that outpace severity trends, achieving a cumulative premium change of more than 80% since 2018 in the medical professional liability market.
• We also continue to forgo renewal and new business opportunities in this loss environment that we believe do not meet our expectation of rate adequacy.
• We believe our focus on our organization's Mission, Vision and Core Values enhances our market position and differentiates us from other insurers.

Industry Context

StockSavvy.ai notes that ProAssurance operates in a highly competitive and consolidating healthcare insurance market, particularly in Medical Professional Liability. The industry faces challenges from rising social inflation, eroding tort reforms, and the increasing complexity of healthcare delivery systems. The company's strategic focus on disciplined underwriting, rate adequacy, and leveraging technology like AI for risk selection and claims management aligns with broader industry efforts to combat these pressures. The pending merger with The Doctors Company reflects a trend towards consolidation to achieve greater scale and breadth of capabilities in a dynamic market.

Comparison to Industry Standards

• The company's combined ratio of 106.6% in 2025, while improved, remains above the typical industry target of below 100% for underwriting profitability, suggesting continued challenges in achieving consistent underwriting gains.
• The A (Excellent) claims paying rating from AM Best for its insurance subsidiaries is a strong rating, comparable to many well-established regional and national specialty insurers, indicating solid financial strength.
• The company's cumulative premium change of over 80% since 2018 in the medical professional liability market suggests a more aggressive pricing strategy compared to some competitors who may prioritize market share over immediate profitability, as noted in the filing.

Corporate Governance

Legal Proceedings

• The company's insurance subsidiaries are involved in various legal actions arising from claims made under insurance policies, which are considered part of the loss reserving process.
• Management and legal counsel are of the opinion that these legal actions will not have a material adverse effect on the company's financial position or results of operations.
• No material reserves were established for corporate legal actions as of December 31, 2025.

Related Party Transactions

• ProAssurance Corporation charges its core domestic operating subsidiaries (Specialty P&C and Workers' Compensation Insurance segments) a management fee for services provided, based on the extent of services and gross premium written by the subsidiary.
• PPM Insurance Services, Inc. provides necessary services for Preferred Physicians Medical Risk Retention Group (PPM), and NORCAL Insurance Company holds a $5 million surplus note and reinsures 100% of PPM's business through a quota share reinsurance agreement.

Stakeholder Impact

• Shareholders: The proposed merger with The Doctors Company offers a fixed cash consideration of $25.00 per share, providing a clear exit strategy and value realization, though the suspension of quarterly dividends impacts current income.
• Employees: The company emphasizes an 'Employer of Choice' culture with competitive pay, benefits, flexible work arrangements, and Diversity, Equity, and Inclusion (DEI) initiatives, aiming to attract and retain talent. The merger could lead to integration-related changes.
• Customers/Policyholders: The focus on rate adequacy and disciplined underwriting may lead to higher premiums in some segments, while enhanced claims management and innovation (e.g., AI in claims processing) aim to improve service and outcomes.
• Creditors: The company maintains a healthy consolidated debt to capital ratio of 0.24 to 1.0 and strong financial strength ratings, indicating a solid ability to meet debt obligations.
• Regulators: The company is actively engaged in obtaining necessary regulatory approvals for the merger and complying with evolving data security and privacy laws, demonstrating adherence to regulatory frameworks.

Next Steps

• Complete the merger with The Doctors Company, pending regulatory approvals in California and Pennsylvania, with an anticipated closing by June 30, 2026.
• Continue to pursue profitable underwriting opportunities, emphasizing rate adequacy and disciplined underwriting.
• Further invest in innovation solutions, including artificial intelligence and process automation, to enhance risk selection, decision making, and workflows.
• Monitor and adjust medical cost management initiatives in the Workers' Compensation segment to address severity trends.
• Utilize the remaining Board authorization of $55.9 million for share repurchases or debt retirement.
• Finalize the sale of the Birmingham, AL property, for which a Letter of Intent was signed in December 2025.

Key Dates

Recommendation

The company is in the advanced stages of a definitive merger agreement with The Doctors Company, with a fixed cash consideration of $25.00 per share. For existing shareholders, the primary investment decision revolves around the certainty and timing of this acquisition. Holding shares until the anticipated closing date (June 30, 2026) allows shareholders to receive the full merger consideration, assuming all conditions are met. Selling now would realize current market value and avoid any residual merger-related risks, such as regulatory delays or termination. Given the fixed price, there is limited upside beyond the $25.00 per share, making a 'hold' recommendation appropriate for those awaiting the merger's completion, while new investors might consider arbitrage opportunities if the stock trades below the offer price.

Keywords

Insurance, Medical Professional Liability, Workers' Compensation, SEC Filing, 10-K, Financial Results, Merger, Acquisition, The Doctors Company, Underwriting, Loss Reserves, Combined Ratio, Operating Ratio, Investment Income, Cybersecurity, Risk Management, Specialty P&C, Reinsurance, Shareholder Equity, Corporate Governance, AI, Medical Technology Liability